

Substitute for Form 1449/PTO

MAR 15 2004

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/657,033
Filing Date	09-05-2003
First Named Inventor	Paul John Edwards
Art Unit	1614
Examiner Name	TBA
Attorney Docket Number	PC25402A

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	Cite No. ¹	DOCUMENT NUMBER	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ²			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ⁴ Number ⁵ Kind Code ⁶ (if known)				
70		WO 02/085860	10/31/2002	Jones, et al		

EXAMINER:

T. H. Solola

DATE CONSIDERED:

4-18-05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.
 Substitute for form 1449/PTO **Complete if Known**

Substitute for form 1449/PTO

MAR 15 2004

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/657,033
Filing Date	09-05-2003
First Named Inventor	Paul John Edwards
Art Unit	1814
Examiner Name	TBA
Attorney Docket Number	PC25402A

NON PATENT LITERATURE DOCUMENTS

[illegible]

EXAMINER:

T. A. Solola

DATE CONSIDERED:

4-18-05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Includes copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.1). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document and/or WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.** Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO



(Use as many sheets as necessary)

Application Number	10/657,033
Filing Date	September 5, 2003
First Named Inventor	Paul John Edwards
Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	PC25402A

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
40	AI	BERGE, et al., "Pharmaceutical Salts," <i>Journal of Pharmaceutical Sciences</i> , 1977, 1-19, vol. 66, No. 1.	
	AJ	BIGHLEY, et al., "Salt Forms of Drugs and Absorption," <u>Encyclopedia of Pharmaceutical Technology</u> , Marcel Dekker Inc. New York, 1996, pages 453-497, vol. 13.	
	AK	BUNDGAARD, H., <u>Design of Prodrugs</u> , 1985, Elsevier Science Publishers, Amsterdam, New York, Oxford.	
	AL	CAREY, et al., "Part A: Structure and Mechanisms," <u>Advanced Organic Chemistry</u> , 3 rd Edition, Plenum Press, New York, London, 1990.	
	AM	FERRES, et. al., "Pro-Drugs of β -Lactam Antibiotics," <u>Drugs of Today</u> 1983, 499-538, Vol. 19, No. 9.	
	AN	GENIN, M. et al., "Novel 1,5-Diphenylpyrazole Nonnucleoside HIV-1 Reverse Transcriptase Inhibitors with Enhanced Activity Versus The Zalcitabine-Resistant P236L Mutant: Lead Identification and SAR of 3- and 4-Substituted Derivatives," <i>Journal of Medicinal Chemistry</i> , 2000, vol. 43, page 1034-1040.	
	AO	GREENE, T. <u>Protective Groups in Organic Synthesis</u> 2 nd Edition 1991, John Wiley & Sons, Inc., New York, Chichester, Brisbane, Toronto, Singapore.	
	AP	HAJIMORAD, et al., "Some Observations On The Binding Properties Of Alfalfa Mosaic Virus To Polystyrene And Its Significance To Indirect ELISA," <u>Archives of Virology</u> , 1991, pages 219-235, Vol. 117.	
	AQ	KATRITZKY, et al. "The Structure, Reactions, Synthesis and Uses of Heterocyclic Compounds," <u>Comprehensive Heterocyclic Chemistry</u> Vol. 1-11, Pergamon Press, Oxford, New York, Toronto, Sydney, Paris, Frankfurt, 1984.	

EXAMINER:

T. A. Solov

DATE CONSIDERED:

4-18-05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). **See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ***Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ****Indef document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *****Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.** Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.